[go: up one dir, main page]

EP0843573B1 - Appareil de traitement de l'os par les ultrasons - Google Patents

Appareil de traitement de l'os par les ultrasons Download PDF

Info

Publication number
EP0843573B1
EP0843573B1 EP95937426A EP95937426A EP0843573B1 EP 0843573 B1 EP0843573 B1 EP 0843573B1 EP 95937426 A EP95937426 A EP 95937426A EP 95937426 A EP95937426 A EP 95937426A EP 0843573 B1 EP0843573 B1 EP 0843573B1
Authority
EP
European Patent Office
Prior art keywords
signal
bone
ultrasonic
pulse
mhz
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP95937426A
Other languages
German (de)
English (en)
Other versions
EP0843573A1 (fr
EP0843573A4 (fr
Inventor
Jonathan J. Kaufman
Allessandro E. Chiabrera
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Capstone Holding Corp
Original Assignee
Orthologic Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orthologic Corp filed Critical Orthologic Corp
Publication of EP0843573A1 publication Critical patent/EP0843573A1/fr
Publication of EP0843573A4 publication Critical patent/EP0843573A4/fr
Application granted granted Critical
Publication of EP0843573B1 publication Critical patent/EP0843573B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N7/00—Ultrasound therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B2017/00017—Electrical control of surgical instruments
    • A61B2017/00137—Details of operation mode
    • A61B2017/00141—Details of operation mode continuous, e.g. wave
    • A61B2017/00146—Details of operation mode continuous, e.g. wave with multiple frequencies
    • A61B2017/0015—Details of operation mode continuous, e.g. wave with multiple frequencies applied simultaneously
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B2017/00017—Electrical control of surgical instruments
    • A61B2017/00137—Details of operation mode
    • A61B2017/00154—Details of operation mode pulsed
    • A61B2017/00172—Pulse trains, bursts, intermittent continuous operation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/28—Bones
    • A61F2002/286—Bone stimulation by mechanical vibrations for enhancing ossification
    • A61F2002/2864—Bone stimulation by mechanical vibrations for enhancing ossification by ultrasonic or acoustic vibrations

Definitions

  • the invention pertains to apparatus for non-invasively therapeutically treating bone tissue in vivo.
  • the Kaufman method includes subjecting bone to an ultrasonic acoustic signal pulse of finite duration, and involving a composite sine-wave signal consisting of plural discrete frequencies. These frequencies are spaced in the ultrasonic region to approximately 2 MHz; the excitation signal is repeated substantially in the range from 1 to 1000 Hz.
  • Duarte, U.S. Pat. No. 4,530,360 discloses an apparatus and a method of using ultrasonic energy for therapeutic treatment of bone tissue in vivo, using a pulsed sine wave at substantially a aingle frequency within the range from 1.3 to 2.0 MHz, and at a pulse repetition rate of 100 to 1000Hz.
  • McLeod et al. U.S. Pat. Nos. 5,103,806 and 5,191,880 disclose methods for promoting bone tissue growth and the prevention of osteopenia, using mechanical loading of the bone tissue.
  • the inventors apply a mechanical load to the bone tissue at a relatively low level on the order of between about 10 and about 1000 microstrain, peak to peak, and at a frequency in the range of about 10 to 100 Hertz.
  • Bassett et al. U.S. Patent No. 4,928,959 disclose a method and device for providing active exercise treatment for a patient suffering from a bone disorder.
  • a patient is subjected to an impact load in order to stimulate bone growth, with an impact load sensor being used to monitor the treatment strength.
  • the inventors noted that high frequency (up to 100,000 Hz) force components were important for stimulating bone growth.
  • 5,318,561 (and others), methods are disclosed that incorporate the combined use of a static and time-varying magnetic field to stimulate bone healing and growth. Specific amplitudes and frequencies are disclosed for optimal enhancement of bone growth, based on the theory of "ion-cyclotron resonance".
  • US 5309 898 discloses an apparatus for non-invasively therapeutically treating and/or quantatively evaluating bone tissue.
  • this invention incorporates the realization that fluid flow induced in normal physiological loading is the critically important variable in bone healing, and moreover, includes an efficient means for generating this fluid flow in living tissues.
  • this invention includes a means for stimulating fluid flow at relatively high frequencies by taking unique advantage of the nonlinear characteristics of ultrasound propagation in an ionic-fluid-saturated porous medium such as bone.
  • this invention incorporates the important features of repetitive stimulation in analogy to that found in normal physiologic loading, and of adaptive feedback control for ensuring that an optimal signal dose arrives at the desired bone tissue site.
  • Another object is to meet the above object, such that bone healing and bone growth may be more efficiently and more effectively stimulated then heretofore.
  • a specific object is to achieve the above objects with an optimal set of ultrasonic signals chosen with respect to the specific nonlinear characteristics of their propagation within the bone tissue and with respect to the emulation of physiological loading.
  • a further specific object is to enable adaptive and on-line evaluation of the optimal dose of an applied exogenous ultrasonic acoustic therapeutic signal.
  • an apparatus for non-invasive therapeutic treatment of a bone tissue in vivo comprising means for controlling the production of a preselected periodic sine modulated therapeutic ultrasonic sine signal and means for preselecting a power intensity of the therapeutic signal characterized in that the means for preselecting the power intensity of the signal comprises:
  • the invention in its presently preferred form achieves the foregoing objectives by subjecting bone to an ultrasonic acoustic excitation signal pulse of finite duration in the ultrasonic region of approximately 1.1 MHz, supplied to a transducer adapted for acoustic coupling to the skin surface overlying a bone; the excitation signal is repeated in the range of about 1 Hz to about 5000 Hz.
  • the exposure time for therapy is chosen to be in the range of 5 minutes to 1 hour, for 1 to 3 times a day, for a period of days as necessary for complete healing or for promoting bone growth or ingrowth.
  • an initial interrogating acoustic ultrasonic pulse is preferably transmitted in order to determine the actual thickness of soft tissue overlying the bone treatment site.
  • the bone treatment site may be the zone of fracture, the interface between an implanted device (e.g., hip) and bone, or an intact bone which has reduced bone mass, as for example with osteoporosis.
  • the input signal amplitude supplied to the transducer is adjusted to ensure that the spatial-average time-average (SATA) power density (i.e., intensity I SATA ) reaching the near-bone surface is approximately 45 mW/cm 2 .
  • the received signal is also monitored during the actual treatment exposure to ensure that the patient is receiving the prescribed therapy during the prescribed treatment time.
  • SATA spatial-average time-average
  • FIG. 1 diagrammatically illustrates selected interconnected components for constructing an apparatus for performing methods associated with this invention, namely for non-invasively therapeutically treating bone tissue in vivo, to stimulate bone growth (ingrowth) and bone healing.
  • These components are, in general, commercially available from different sources and will be identified as the detailed description of their total operation is provided.
  • the bone locale 10 such as a fracture site, an area affected by osteoporosis, or any other part of bone tissue to be treated non-invasively, is shown surrounded by soft tissue 12.
  • Ultrasonic transducer 14 is placed near bone locale 10, adjacent soft tissue 12.
  • transducer 14 can be a rectangular piezoelectric transducer of approximately one by two inches placed on the surface of the skin overlying the fractured bone at approximately the site of fracture.
  • the transducer may have a single piezoelectric element that is adapted for both transmitting and receiving, or one transmitting element and one or more receiving elements (not specifically shown).
  • Such transducers are available from Parallel Designs, Inc., Phoenix, AZ.
  • transducer 14 is used for signal launching and receiving the launched signals after reflecting back from bone 10 and passing through surrounding soft tissue 12.
  • An ultrasonic couplant (not shown) such as a gel is applied between transducer 14 and the patient's outer skin surrounding the soft tissue 12.
  • a signal processing unit 16 which specifically may be a computer, and more specifically, a personal computer, such as the 66 MHz Pentium available from Gateway 2000, Inc., North Sioux City, South Dakota. As its designation suggests, this computer contains a 66 MHz clock-pulse generator, and an Intel 586 (Pentium) processor, with provision for keyboard instructions at 18.
  • Computer 16 performs constant on-line monitoring of proper functioning of the apparatus according to the present invention. Specifically, computer 16 ensures providing a prescribed therapy to a patient by responding to and watching the reflected signals to calculate an appropriate treatment dose of ultrasonic exposure.
  • a sinusoidal function-generator at a card 20 is relied upon to generate an excitation signal, which is supplied to launch transducer 14, via power amplifier means 22.
  • the power amplifier is suitably Model No. 2401, an RF power amplifier product of EIN, Inc., Rochester, NY. This product provides a 50 dB gain over the range 20 kHz to 10 MHz.
  • the excitation signal produced by the generator at card 20 is a pulsed sine wave signal in the ultrasonic range to about 2 MHz, which is sine wave modulated in the range of 0 to 25 kHz.
  • the generator at card 20 may suitably be a commercially available waveform synthesizer, a product of Quatech, Inc., Akron, OH, identified by Quatech part No. WSB-100. This waveform synthesizer provides generation of analog signals independent of host computer 16, allowing full processor power to be used for other tasks, including calculation of waveform data.
  • Card 20 preferably has the capacity to generate an output signal comprising literally thousands of points in the indicated ultrasonic frequency range.
  • Another card 24 is also shown installed in computer 16, for converting analog signals obtained from the receiving element of transducer 14 into digital format for further processing in computer 16.
  • a known in the art switching element (not shown) can be used for disconnecting transducer 14 from card 20 and connecting it to card 24 which latter card may suitably contain a 100 MHz waveform digitizer, part number STR*8100, a product available from SONIX, of Springfield, VA.
  • a connection 26 (shown by broken lines) connects signal-generator card 20 to A/D card 24, for synchronizing purposes and for the purposes of digitizing the reflected waveform, to enable computer 16 to perform a suitably compensated, continuously operative updating average of the signals received at transducer 14.
  • a conventional reamplifier (not shown) for increasing the level of the reflected waveform before being input to card 24 can be included.
  • an initial interrogating acoustic ultrasonic pulse is preliminarily transmitted by card 20 via transducer 14.
  • An exponentially damped sinusoidal signal at 1.1 MHz, with a duration of about 2 ⁇ s could be an example of such a pulse.
  • Transducer 14 is then used as a receiver to record the reflected signal from the near bone surface.
  • the arrival time of the reflected signal provides a measure of the round-trip transit time, ⁇ , for the acoustic pulse to travel from the transducer through the soft tissue to the bone surface (where it is partially reflected), and back through the soft tissue.
  • an estimate of soft tissue thickness may be used for adjusting the input signal amplitude to ultrasonic transducer 14 to ensure that the optimal power intensity impinges on the fractured bone.
  • This is preferably carried out as follows.
  • an above mentioned estimate of soft tissue thickness, d s [cm] is acquired.
  • a nominal value for ultrasonic attenuation at 1.1 MHz in soft tissue can be obtained as ⁇ s ⁇ 1 dB/cm.
  • the following formula may then be used to construct a look-up table which provides the necessary values for the relative amplification, A, applied to the input signal.
  • the associated input signal amplifications to be used may be calculated for a range of soft tissue thicknesses: Soft Tissue Thickness [cm] Signal Amplification 1 1.12 2 1.26 3 1.41 4 1.58 5 1.78 6 2.00
  • the therapeutic signal is specifically designed to optimally stimulate the fracture healing process.
  • the optimal signal characteristics which are set forth in more detail below, are derived using nonlinear wave-propagation theory and stimulate bone healing and growth through its direct effect on fluid flow.
  • the reliance on acoustic microstreaming as the primary bio-effective aspect of the endogenous ultrasonic signal has led to a more effective and efficacious treatment for bone repair, in contrast to the prior art, which relies on, for example, the endogenous piezoelectricity of bone (see Duarte, supra), the generation of mechanical strains in the bone tissue (see Bassett et al., U.S. Patents Nos. 4,928,959 and 5,046,484, and McLeod et al., supra), or on the induction of electrical currents in bone tissue (see Ryaby et al., U.S. Patent No. 4,266,533).
  • Fluid flow is assumed to be the fundamental entity which, when Stimulated, will enhance bone growth and healing.
  • a generalized Darcy equation can be used to express the relationship between fluid flux and related quantities in the porous medium by taking into account the contribution of Maxwell's stress tensor in the fluid: ( ⁇ k 0 + ⁇ ⁇ ⁇ F f 0 ⁇ ⁇ t ) ⁇ w ⁇ t ⁇ - ⁇ p F + ⁇ F ( ⁇ 2 ⁇ F ) ⁇ F + ⁇ F 2 6 ⁇ 0 ⁇ ( ⁇ F ⁇ F )
  • ⁇ (kgm -1 s -1 ) is the viscosity of the fluid
  • ⁇ ⁇ is the (high frequency) tortuosity of the porous medium
  • k 0 (m 2 ) is the (low frequency) Darcy permeability
  • ⁇ F and ⁇ 0 (Fm -1 ) are the dielectric permittivities of the fluid and vacuum, respectively ( ⁇ F >> ⁇ 0 )
  • f 0 is the volummetric porosity
  • ⁇ F (kgm -3 ) is
  • ⁇ F (V) is the scalar electric potential in the fluid that results from the perturbation of the endogenous electric potential by the exogenous acoustic exposure (i.e., the ultrasonic signal).
  • the endogenous electric potential arises from several sources, including primarily the interaction of the ionic fluid with the charged solid matrix surface. It also should be noted that the electric field within the fluid is equal to - ⁇ F (Vm -1 ).
  • the pressure in the fluid is denoted by p F (Nm -2 ), and is the pressure resulting from the interaction of the exogenous acoustic exposure with the fluid-filled porous bone structure.
  • both constant and oscillatory fluid flows for promoting bone growth and repair can be stimulated through appropriate design of the applied acoustic signal that will be discussed below in more detail.
  • the above theory clarifies that for obtaining both constant and oscillatory fluid flows at rates relevant to therapeutic bone dynamics, the leading term is the square of the applied ultrasonic signal p(t), i.e., p 2 (t).
  • p(t) the applied ultrasonic signal
  • the signals are specifically designed to be modulated by relatively high frequencies (generally above 500 Hz) in a pulsed excitation mode, which permits the bone tissue to respond maximally during each stimulatory cycle.
  • the received ultrasonic signal is used as a means for providing on-line fault detection, to ensure that the required therapeutic signal is reaching the fracture site during all periods of the treatment prescribed to a patient.
  • General signal-processing/display/storage software for the signal processing control and operation of computer 16 is not shown but will be understood to be contained on a conventional floppy disk loaded at 28 into computer 16; this software is suitably the MATLAB-386, available from The MathWorks, Inc., Natick, MA. Further software (not illustrated) includes the signal processing toolbox, also available from MathWorks, as well as Fortran 5.0, available from Microsoft Corporation, Bothell, WA, and LabView, available from National Instruments Corporation, Austin, TX.
  • bony member 10 surrounded with soft tissue 12 is placed next to ultrasound transducer 14.
  • An ultrasound signal is transmitted from transducer 14, passes through soft tissue 12, is partially transmitted into the bony member, and is partially reflected from bone tissue 10 back through soft tissue 12 to be received by the receiving element (not specifically shown) of transducer 14.
  • the transmitted ultrasound signal is generated using a finite-duration sine-wave signal, which is sine-wave modulated.
  • the constant K is adjusted such that an intensity (I SATA ) of the acoustic ultrasonic wave impinging at the near bone surface is in the range of 20 - 100 mW/cm 2 .
  • amplitude modulation of the carrier signal at a relatively high frequency is specifically used to generate fluid flux at relatively high rates.
  • the amplitude of the signal is adjusted to provide I SATA of approximately 45 mW/cm 2 at the fracture site.
  • dynamic strains induced in the bone tissue are primarily in the ultrasonic spectral region, that is, at the nominal frequency of the applied ultrasonic signal. For the presently preferred embodiment, this frequency is 1.1 MHz, and in all cases is above 25 kHz. Additionally, the strain levels induced in the bone tissue, assuming a characteristic length of 10 centimeters, are extremely small. The peak-to-peak strain value can be reasonably well approximated from the well known equation for induced particle displacements associated with an ultrasonic input (see for example Physical Principles of Medical Ultrasonics , ed., CR Hill, Halsted Press, 1986, p. 57).
  • ⁇ 0 is the unperturbed bone density
  • c is the velocity of ultrasound in the bone
  • f is the ultrasonic frequency.
  • the three presently preferred embodiments include ultrasonic signals that are specified as follows:
  • the above-mentioned Quatech card is used in conjunction with another instrument, suitably a Wavetek Model No. 178 Programmable Waveform Synthesizer available from Wavetek, San Diego, California.
  • the Quatech card outputs the modulating waveform as input to the Wavetek Waveform Synthesizer to amplitude modulate the 1.1 MHz carrier signal.
  • An enlarged class of ultrasonic therapeutic signals includes waveforms, which are frequency modulated in addition to them being amplitude modulated in order to take further advantage of the nonlinear propagation characteristics of bone tissue.
  • waveforms which are frequency modulated in addition to them being amplitude modulated in order to take further advantage of the nonlinear propagation characteristics of bone tissue.
  • sweeping not only the modulating frequency but also the carrier frequency contributes both to changing and manipulating so-called hot and cold spots in ultrasonic treating a tissue, and to bringing energy to a bone at different frequencies.
  • a sine wave can be assumed to be used to denote a sinusoidal function at a single frequency or a sinusoidal function with frequency modulation, i.e., a swept sine wave. It is also appreciated that for most cases the modulating frequency in these signals is not supposed to assume the zero value. However, in some concrete instances it can begin or end at or pass through this value.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Surgical Instruments (AREA)
  • Percussion Or Vibration Massage (AREA)

Claims (12)

  1. Dispositif pour traitement thérapeutique non envahissant d'un tissu osseux in vivo comprenant des moyens (14, 16, 20, 24) pour commander la production d'un signal sinusoïdal ultrasonique thérapeutique modulé à sinusoïde périodique présélectionné et un moyen pour présélectionner l'intensité de puissance du signal thérapeutique caractérisé en ce que le moyen de présélection de l'intensité de puissance du signal comprend :
    i) un moyen pour transmettre une impulsion ultrasonique acoustique d'interrogation au tissu osseux à travers un tissu tendre recouvrant le tissu osseux ;
    ii) un moyen pour recevoir une partie dudit signal d'interrogation réfléchi par le tissu osseux ;
    iii) un moyen pour déterminer l'épaisseur du tissu tendre au moyen de ladite partie réfléchie ; et
    iv) un moyen pour régler l'amplitude du signal ultrasonique thérapeutique en réponse à l'épaisseur du tissu tendre déterminée par le moyen pour déterminer l'épaisseur du tissu tendre au moyen de ladite partie réfléchie afin de garantir qu'une intensité de puissance moyenne spatiale, moyenne temporelle atteint le tissu osseux à une valeur prédéterminée.
  2. Dispositif selon la revendication 1, dans lequel le signal thérapeutique est modulé en amplitude et le moyen pour régler l'amplitude comprend un moyen pour :
    i) sélectionner une fréquence porteuse dans la gamme entre 25 kHz et 2 MHz ;
    ii) sélectionner une fréquence de modulation dans une gamme jusqu'à environ 25 kHz;
    iii) sélectionner un indice de modulation jusqu'à 1000 ;
    iv) sélectionner une largeur d'impulsion entre 0,1 ms et 1,0 s ;
    v) sélectionner une durée de cycle entre 0,2 ms et 1,0 s ;
    vi) sélectionner une intensité dans une gamme entre 20 mW/cm2 et 100 mW/cm2 ; et
    vii) sélectionner une durée d'exposition entre 5 minutes et une heure, de 1 à 3 fois par jour.
  3. Dispositif selon la revendication 2, dans lequel le moyen sélectionne :
    i) une fréquence porteuse de 1,1 MHz ;
    ii) une fréquence de modulation de 20 kHz ;
    iii) un indice de modulation de 0,3 ;
    iv) une largeur d'impulsion de 0,5 ms ;
    v) une durée de cycle de 5 ms ; et
    vi) une intensité de 45 mW/cm2.
  4. Dispositif selon la revendication 2, dans lequel le moyen sélectionne :
    i) une fréquence porteuse de 1,1 MHz ;
    ii) une fréquence de modulation de 20 kHz ;
    iii) un indice de modulation de 0,3 ;
    iv) une largeur d'impulsion de 0,1 ms ;
    v) une durée de cycle de 0,5 ms ; et
    vi) une intensité de 45 mW/cm2.
  5. Dispositif selon la revendication 2, dans lequel le moyen pour régler l'amplitude comprend en outre un moyen pour produire jusqu'à 5000 répétitions d'impulsions dans un cycle, chaque impulsion et une pause pour une répétition étant entre 0,1 ms et 1,0 s.
  6. Dispositif selon la revendication 5, dans lequel le moyen pour régler l'amplitude sélectionne :
    i) une fréquence porteuse de 1,1 MHz ;
    ii) une fréquence de modulation de 5 kHz ;
    iii) un indice de modulation de 0,3 ;
    iv) une largeur d'impulsion de 4 ms ;
    v) une durée de cycle de 1 s, chaque impulsion et pause durant pendant 8 ms, avec 25 répétitions d'impulsions dans le cycle ; et
    vi) une intensité de 45 mW/cm2.
  7. Dispositif selon la revendication 5, dans lequel le signal sinusoïdal ultrasonique thérapeutique modulé à sinusoïde périodique présélectionné est un signal modulé en fréquence et en amplitude, et dans lequel le moyen pour régler l'amplitude comprend en outre un moyen pour sélectionner une gamme de balayage de la fréquence porteuse entre la valeur sélectionnée de la fréquence porteuse et 2 MHz ; et sélectionner une gamme de balayage de la fréquence de modulation entre la valeur sélectionnée de la fréquence de modulation et 25 MHz.
  8. Dispositif selon la revendication 7, dans lequel le moyen pour régler l'amplitude sélectionne :
    i) une fréquence porteuse de 1,1 MHz ;
    ii) une fréquence de modulation de 500 Hz, ladite fréquence de modulation ayant une gamme de balayage entre 500 Hz et 2000 Hz ;
    iii) un indice de modulation de 1 ;
    iv) une largeur d'impulsion de 4 ms ;
    v) une durée de cycle de 1 s, chaque impulsion et pause durant 8 ms ; et avec 25 répétitions d'impulsions dans le cycle ;
    vi) une intensité de 45 mW/cm2.
  9. Dispositif selon l'une quelconque des revendications 1 à 8, dans lequel le moyen pour déterminer l'épaisseur du tissu tendre utilise la formule : ds = vs t/2 où ds est l'épaisseur désirée vs est la vitesse des ultrasons dans le tissu tendre ; et t est un temps de transit aller-retour de ladite impulsion acoustique depuis une source de celle-ci à travers le tissu tendre, jusqu'au tissu osseux, et de retour à travers le tissu tendre.
  10. Dispositif selon l'une quelconque des revendications 1 à 9, dans lequel le moyen pour émettre une impulsion ultrasonique acoustique d'interrogation sélectionne un signal sinusoïdal atténué exponentiellement à 1,1 MHz, d'une durée d'environ 2 µs.
  11. Dispositif selon la revendication 1, dans lequel le signal sinusoïdal ultrasonique thérapeutique modulé par sinusoïde est sélectionné dans le groupe consistant en un signal sinusoïdal à modulation par onde sinusoïdale à balayage de fréquence, un signal sinusoïdal à balayage de fréquence modulé par onde sinusoïdale, et un signal sinusoïdal à balayage de fréquence modulé par onde sinusoïdale à balayage de fréquence.
  12. Dispositif selon la revendication 1, qui comprend en outre un moyen pour générer ladite impulsion ultrasonique d'interrogation.
EP95937426A 1994-10-25 1995-10-04 Appareil de traitement de l'os par les ultrasons Expired - Lifetime EP0843573B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/329,015 US5547459A (en) 1994-10-25 1994-10-25 Ultrasonic bone-therapy apparatus and method
US329015 1994-10-25
PCT/US1995/013086 WO1996012519A1 (fr) 1994-10-25 1995-10-04 Therapie de traitement de l'os par les ultrasons et procede associe

Publications (3)

Publication Number Publication Date
EP0843573A1 EP0843573A1 (fr) 1998-05-27
EP0843573A4 EP0843573A4 (fr) 1999-07-21
EP0843573B1 true EP0843573B1 (fr) 2003-12-10

Family

ID=23283485

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95937426A Expired - Lifetime EP0843573B1 (fr) 1994-10-25 1995-10-04 Appareil de traitement de l'os par les ultrasons

Country Status (8)

Country Link
US (2) US5547459A (fr)
EP (1) EP0843573B1 (fr)
JP (1) JPH10509605A (fr)
AT (1) ATE255935T1 (fr)
AU (1) AU3954695A (fr)
DE (1) DE69532305T2 (fr)
ES (1) ES2210320T3 (fr)
WO (1) WO1996012519A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020154633A1 (fr) 2019-01-25 2020-07-30 Acoustic Sciences Associates, Llc Stimulation ultrasonore de structures de tissu musculo-squelettique

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5547459A (en) * 1994-10-25 1996-08-20 Orthologic Corporation Ultrasonic bone-therapy apparatus and method
US6517487B1 (en) 1995-03-01 2003-02-11 Lunar Corporation Ultrasonic densitometer with opposed single transducer and transducer array
GB9617749D0 (en) * 1996-08-23 1996-10-02 Young Michael J R Improved apparatus for ultrasonic therapeutic trteatment
US7169123B2 (en) * 1997-01-22 2007-01-30 Advanced Medical Optics, Inc. Control of pulse duty cycle based upon footswitch displacement
US6780165B2 (en) 1997-01-22 2004-08-24 Advanced Medical Optics Micro-burst ultrasonic power delivery
US7108663B2 (en) * 1997-02-06 2006-09-19 Exogen, Inc. Method and apparatus for cartilage growth stimulation
US7789841B2 (en) 1997-02-06 2010-09-07 Exogen, Inc. Method and apparatus for connective tissue treatment
US5904659A (en) * 1997-02-14 1999-05-18 Exogen, Inc. Ultrasonic treatment for wounds
KR20010006565A (ko) * 1997-04-18 2001-01-26 텔리쉬, 로저 제이. 흉골 치료 촉진을 위한 초음파 적용 장치
WO1999008596A1 (fr) 1997-08-19 1999-02-25 Philipp Lang Mesure du fluide interstitiel propre aux capillaires utilisant des methodes et des dispositifs echographiques
US20020055702A1 (en) * 1998-02-10 2002-05-09 Anthony Atala Ultrasound-mediated drug delivery
US6585649B1 (en) 1998-05-02 2003-07-01 John D. Mendlein Methods and devices for improving ultrasonic measurements using multiple angle interrogation
US6013031A (en) * 1998-03-09 2000-01-11 Mendlein; John D. Methods and devices for improving ultrasonic measurements using anatomic landmarks and soft tissue correction
US6077224A (en) * 1998-03-23 2000-06-20 Lang; Philipp Methods and device for improving broadband ultrasonic attenuation and speed of sound measurements using anatomical landmarks
PT1076586E (pt) 1998-05-06 2007-01-31 Exogen Inc Ligaduras ultrasónicas
DE19832272C1 (de) 1998-07-17 2000-03-16 Cbm Cross Boarder Management U Gelenk-Endoprothese sowie Verfahren zum Festigen ihres Sitzes
WO2000004831A1 (fr) 1998-07-21 2000-02-03 Acoustic Sciences Associates Imagerie structurale synthetique et estimation de volume d'organes tissulaires biologiques
WO2000021440A1 (fr) * 1998-10-14 2000-04-20 Lenhardt Martin L Masque d'acouphene
US6231528B1 (en) 1999-01-15 2001-05-15 Jonathan J. Kaufman Ultrasonic and growth factor bone-therapy: apparatus and method
US6251088B1 (en) 1999-05-12 2001-06-26 Jonathan J. Kaufman Ultrasonic plantar fasciitis therapy: apparatus and method
US7410469B1 (en) 1999-05-21 2008-08-12 Exogen, Inc. Apparatus and method for ultrasonically and electromagnetically treating tissue
EP1408853A1 (fr) 1999-06-14 2004-04-21 Exogen, Inc. Procede et kit de reparation tissulaire induite par cavitation avec des ultrasons de faible intensite
US6372031B1 (en) * 1999-08-03 2002-04-16 Milliken & Company Washable coloring compositions comprising low molecular-weight styrene-maleic anhydride copolymers
EP1110509A1 (fr) * 1999-12-21 2001-06-27 Tomaso Vercellotti Dispositif chirurgical pour chirurgie osseuse
US6675048B2 (en) 2000-05-08 2004-01-06 International Rehabilitative Sciences, Inc. Electro-medical device for use with biologics
US6560487B1 (en) * 2000-05-08 2003-05-06 International Rehabilitative Sciences, Inc. Electro-medical device for use with biologics
US6393328B1 (en) * 2000-05-08 2002-05-21 International Rehabilitative Sciences, Inc. Multi-functional portable electro-medical device
US7747332B2 (en) 2000-05-08 2010-06-29 International Rehabilitative Sciences, Inc. Electrical stimulation combined with a biologic to increase osteogenesis
US6964647B1 (en) 2000-10-06 2005-11-15 Ellaz Babaev Nozzle for ultrasound wound treatment
JP4126228B2 (ja) 2000-10-25 2008-07-30 エクソジェン インコーポレイテッド 変換器取付用組立体
US6601581B1 (en) 2000-11-01 2003-08-05 Advanced Medical Applications, Inc. Method and device for ultrasound drug delivery
AU2002227147A1 (en) * 2000-11-02 2002-05-15 Keith L March Method and system for modulation of oscillating signals to enhance biologic effects
US6761729B2 (en) 2000-12-22 2004-07-13 Advanced Medicalapplications, Inc. Wound treatment method and device with combination of ultrasound and laser energy
US6533803B2 (en) 2000-12-22 2003-03-18 Advanced Medical Applications, Inc. Wound treatment method and device with combination of ultrasound and laser energy
US7914470B2 (en) 2001-01-12 2011-03-29 Celleration, Inc. Ultrasonic method and device for wound treatment
US8235919B2 (en) * 2001-01-12 2012-08-07 Celleration, Inc. Ultrasonic method and device for wound treatment
US6514220B2 (en) * 2001-01-25 2003-02-04 Walnut Technologies Non focussed method of exciting and controlling acoustic fields in animal body parts
US6960173B2 (en) * 2001-01-30 2005-11-01 Eilaz Babaev Ultrasound wound treatment method and device using standing waves
US20020151940A1 (en) * 2001-03-08 2002-10-17 University Of California Transcutaneous spine trauma and disorders treatment using ultrasonically induced confined heat (ulich) zone
US6623444B2 (en) 2001-03-21 2003-09-23 Advanced Medical Applications, Inc. Ultrasonic catheter drug delivery method and device
US6478754B1 (en) 2001-04-23 2002-11-12 Advanced Medical Applications, Inc. Ultrasonic method and device for wound treatment
US20030032898A1 (en) 2001-05-29 2003-02-13 Inder Raj. S. Makin Method for aiming ultrasound for medical treatment
US7846096B2 (en) 2001-05-29 2010-12-07 Ethicon Endo-Surgery, Inc. Method for monitoring of medical treatment using pulse-echo ultrasound
US7429248B1 (en) 2001-08-09 2008-09-30 Exogen, Inc. Method and apparatus for controlling acoustic modes in tissue healing applications
AUPR773901A0 (en) * 2001-09-18 2001-10-11 University Of Queensland, The Fracture cuff
US6997935B2 (en) * 2001-11-20 2006-02-14 Advanced Medical Optics, Inc. Resonant converter tuning for maintaining substantially constant phaco handpiece power under increased load
CN1507333A (zh) * 2002-01-18 2004-06-23 ������������ʽ���� 骨软骨病治疗方法和骨软骨病治疗设备
US6599246B1 (en) * 2002-01-25 2003-07-29 Kenneth W. Coffey Apparatus and method for substantially stationary transducer therapeutic ultrasound treatment
JP4243499B2 (ja) * 2002-06-11 2009-03-25 富士通株式会社 貼合せ基板製造装置及び貼合せ基板製造方法
US20040092921A1 (en) * 2002-10-21 2004-05-13 Kadziauskas Kenneth E. System and method for pulsed ultrasonic power delivery employing cavitation effects
US7316664B2 (en) * 2002-10-21 2008-01-08 Advanced Medical Optics, Inc. Modulated pulsed ultrasonic power delivery system and method
US7077820B1 (en) * 2002-10-21 2006-07-18 Advanced Medical Optics, Inc. Enhanced microburst ultrasonic power delivery system and method
CA2830583C (fr) 2003-03-12 2015-06-09 Abbott Medical Optics Inc. Systeme et procede d'apport de puissance acoustique pulsee utilisant les effets de cavitation
US7846126B2 (en) * 2003-07-14 2010-12-07 Abbott Medical Optics, Inc. System and method for modulated surgical procedure irrigation and aspiration
US8202219B2 (en) * 2004-02-23 2012-06-19 Cyberlogic, Inc. Ultrasonic bone assessment apparatus and method
US7247141B2 (en) 2004-03-08 2007-07-24 Ethicon Endo-Surgery, Inc. Intra-cavitary ultrasound medical system and method
US20050240123A1 (en) * 2004-04-14 2005-10-27 Mast T D Ultrasound medical treatment system and method
US7494467B2 (en) 2004-04-16 2009-02-24 Ethicon Endo-Surgery, Inc. Medical system having multiple ultrasound transducers or an ultrasound transducer and an RF electrode
US7883468B2 (en) 2004-05-18 2011-02-08 Ethicon Endo-Surgery, Inc. Medical system having an ultrasound source and an acoustic coupling medium
US7951095B2 (en) 2004-05-20 2011-05-31 Ethicon Endo-Surgery, Inc. Ultrasound medical system
US7695436B2 (en) * 2004-05-21 2010-04-13 Ethicon Endo-Surgery, Inc. Transmit apodization of an ultrasound transducer array
US7473250B2 (en) 2004-05-21 2009-01-06 Ethicon Endo-Surgery, Inc. Ultrasound medical system and method
US7806839B2 (en) 2004-06-14 2010-10-05 Ethicon Endo-Surgery, Inc. System and method for ultrasound therapy using grating lobes
US20060047230A1 (en) * 2004-08-18 2006-03-02 Roger Talish Non-invasive apparatus and method for vibrational treatment of internal organs
GB0508254D0 (en) * 2005-04-23 2005-06-01 Smith & Nephew Ultrasound device
ITMI20051172A1 (it) * 2005-06-21 2006-12-22 Fernando Bianchetti "dispositivo chirurgico piezoelettrico e metodo per la preparazione di sito implantare"
US7713218B2 (en) * 2005-06-23 2010-05-11 Celleration, Inc. Removable applicator nozzle for ultrasound wound therapy device
US7785277B2 (en) 2005-06-23 2010-08-31 Celleration, Inc. Removable applicator nozzle for ultrasound wound therapy device
CN101330876B (zh) * 2005-12-14 2012-11-07 帝人制药株式会社 具有照射位置确认功能的医疗用超声波装置
US20070299539A1 (en) * 2006-04-12 2007-12-27 Shadi Othman Ultrasound accelerated tissue engineering process
US20070249938A1 (en) * 2006-04-20 2007-10-25 Donald J. Shields Systems, devices, and methods employing therapeutic ultrasound of living tissues
US7431704B2 (en) 2006-06-07 2008-10-07 Bacoustics, Llc Apparatus and method for the treatment of tissue with ultrasound energy by direct contact
US8562547B2 (en) 2006-06-07 2013-10-22 Eliaz Babaev Method for debriding wounds
US8078283B2 (en) 2006-06-20 2011-12-13 Ebr Systems, Inc. Systems and methods for implantable leadless bone stimulation
US7785336B2 (en) * 2006-08-01 2010-08-31 Abbott Medical Optics Inc. Vacuum sense control for phaco pulse shaping
US20080071315A1 (en) * 2006-08-31 2008-03-20 Tamara Colette Baynham Integrated catheter and pulse generator systems and methods
JP4567649B2 (ja) * 2006-11-13 2010-10-20 帝人ファーマ株式会社 トランスデューサ角度調節機構を有する超音波骨折治療器
US7901356B2 (en) * 2006-12-13 2011-03-08 Cyberlogic, Inc. Ultrasonic bone assessment apparatus and method
US9615814B2 (en) * 2006-12-13 2017-04-11 Cyberlogic, Inc. Ultrasonic bone assessment apparatus and method
US20080177221A1 (en) * 2006-12-22 2008-07-24 Celleration, Inc. Apparatus to prevent applicator re-use
US8491521B2 (en) 2007-01-04 2013-07-23 Celleration, Inc. Removable multi-channel applicator nozzle
US20080214965A1 (en) * 2007-01-04 2008-09-04 Celleration, Inc. Removable multi-channel applicator nozzle
US7862510B2 (en) * 2007-02-09 2011-01-04 Cyberlogic, Inc. Ultrasonic bone assessment apparatus and method
JP2010535060A (ja) * 2007-07-30 2010-11-18 リゼンプライム カンパニー リミテッド むくみ治療用超音波装置およびその用途
US20090177122A1 (en) * 2007-12-28 2009-07-09 Celleration, Inc. Methods for treating inflammatory skin disorders
WO2010009141A1 (fr) * 2008-07-14 2010-01-21 Arizona Board Of Regents For And On Behalf Of Arizona State University Procédés et dispositifs de modulation d'une activité cellulaire à l'aide d'ultrasons
US20100016911A1 (en) 2008-07-16 2010-01-21 Ebr Systems, Inc. Local Lead To Improve Energy Efficiency In Implantable Wireless Acoustic Stimulators
US9192353B2 (en) * 2009-10-27 2015-11-24 Innurvation, Inc. Data transmission via wide band acoustic channels
US20110130615A1 (en) * 2009-12-02 2011-06-02 Mishelevich David J Multi-modality neuromodulation of brain targets
US20110178442A1 (en) * 2010-01-18 2011-07-21 Mishelevich David J Patient feedback for control of ultrasound deep-brain neuromodulation
US20110190668A1 (en) * 2010-02-03 2011-08-04 Mishelevich David J Ultrasound neuromodulation of the sphenopalatine ganglion
US20110112394A1 (en) * 2009-11-11 2011-05-12 Mishelevich David J Neuromodulation of deep-brain targets using focused ultrasound
US8972019B2 (en) 2011-01-25 2015-03-03 Kenneth L. Willeford Method and device for treating osteoarthritis noninvasively
US9050627B2 (en) 2011-09-02 2015-06-09 Abbott Medical Optics Inc. Systems and methods for ultrasonic power measurement and control of phacoemulsification systems
WO2013059833A1 (fr) 2011-10-21 2013-04-25 Neurotrek, Inc. Procédé et système de communication directe
WO2014036170A1 (fr) 2012-08-29 2014-03-06 Thync, Inc. Systèmes et dispositifs pour coupler une énergie ultrasonore au corps
JP2014151123A (ja) * 2013-02-13 2014-08-25 Nippon Sigmax Kk 超音波骨折治療装置
US11224767B2 (en) 2013-11-26 2022-01-18 Sanuwave Health, Inc. Systems and methods for producing and delivering ultrasonic therapies for wound treatment and healing
RU2603325C1 (ru) * 2015-06-23 2016-11-27 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Омский государственный технический университет" Устройство активации репаративного остеогенеза
US11877953B2 (en) 2019-12-26 2024-01-23 Johnson & Johnson Surgical Vision, Inc. Phacoemulsification apparatus
US12472094B2 (en) 2020-05-21 2025-11-18 Johnson & Johnson Surgical Vision, Inc. Phacoemulsification probe comprising magnetic sensors and/or multiple independent piezoelectric vibrators
US12178750B2 (en) 2020-11-23 2024-12-31 Johnson & Johnson Surgical Vision, Inc. Removal of cataract debris
US12324770B2 (en) 2021-04-15 2025-06-10 Johnson & Johnson Surgical Vision, Inc. Compensating for imperfect behavior of multi-piezoelectric crystal

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4105017A (en) * 1976-11-17 1978-08-08 Electro-Biology, Inc. Modification of the growth repair and maintenance behavior of living tissue and cells by a specific and selective change in electrical environment
US4315503A (en) * 1976-11-17 1982-02-16 Electro-Biology, Inc. Modification of the growth, repair and maintenance behavior of living tissues and cells by a specific and selective change in electrical environment
BR8107560A (pt) * 1981-11-19 1983-07-05 Luiz Romariz Duarte Estimulacao ultra-sonica da consolidacao de fraturas osseas
US4513749A (en) * 1982-11-18 1985-04-30 Board Of Trustees Of Leland Stanford University Three-dimensional temperature probe
US5106361A (en) * 1988-03-23 1992-04-21 Life Resonances, Inc. Method and apparatus for controlling the growth of non-osseous non-cartilaginous solid connective tissue
US4932951A (en) * 1988-03-23 1990-06-12 Life Resonances, Inc. Method and apparatus for controlling tissue growth and an applied fluctuating magnetic field
US5087336A (en) * 1989-01-09 1992-02-11 Life Resonances, Inc. Methods and apparatus for regulating transmembrane ion movement utilizing selective harmonic frequencies and simultaneous multiple ion regulation
US5067940A (en) * 1988-03-23 1991-11-26 Life Resonances, Inc. Method and apparatus for controlling the growth of cartilage
US5100373A (en) * 1989-01-09 1992-03-31 Life Resonances, Inc. Techniques for controlling osteoporosis using non-invasive magnetic fields
US4818697A (en) * 1986-10-27 1989-04-04 Life Resonances, Inc. Techniques for enhancing the permeability of ions through membranes
US5143588A (en) * 1986-10-27 1992-09-01 Life Resonances, Inc. Techniques for enhancing the permeability of ions through membranes
US5318561A (en) * 1988-03-23 1994-06-07 Life Resonances Inc. Deformable magnetic field aiding coils for use in controlling tissue growth
US5088976A (en) * 1988-03-23 1992-02-18 Life Resonances, Inc. Deformable magnetic field aiding coils for use in controlling tissue growth
US4942868A (en) * 1988-03-30 1990-07-24 Malmros Holding, Inc. Ultrasonic treatment of animals
US4993413A (en) * 1988-09-22 1991-02-19 The Research Foundation Of State University Of New York Method and apparatus for inducing a current and voltage in living tissue
US5077934A (en) * 1989-09-22 1992-01-07 Life Resonances, Inc. Method and apparatus for controlling plant growth
GB2263406A (en) * 1992-01-16 1993-07-28 Shrewsbury Technology Limited Ultrasound therapy apparatus
US5259384A (en) * 1992-07-30 1993-11-09 Kaufman Jonathan J Ultrasonic bone-assessment apparatus and method
US5309898A (en) * 1992-07-30 1994-05-10 Kaufman Jonathan J Ultrasonic bone-therapy and assessment apparatus and method
US5308355A (en) * 1992-11-06 1994-05-03 Alexander Dybbs Ophthalmic surgical instrument and method
US5393296A (en) * 1992-12-09 1995-02-28 Siemens Aktiengesellschaft Method for the medical treatment of pathologic bone
US5524624A (en) * 1994-05-05 1996-06-11 Amei Technologies Inc. Apparatus and method for stimulating tissue growth with ultrasound
US5496256A (en) * 1994-06-09 1996-03-05 Sonex International Corporation Ultrasonic bone healing device for dental application
US5547459A (en) * 1994-10-25 1996-08-20 Orthologic Corporation Ultrasonic bone-therapy apparatus and method
US5520612A (en) * 1994-12-30 1996-05-28 Exogen, Inc. Acoustic system for bone-fracture therapy
US5556372A (en) * 1995-02-15 1996-09-17 Exogen, Inc. Apparatus for ultrasonic bone treatment

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020154633A1 (fr) 2019-01-25 2020-07-30 Acoustic Sciences Associates, Llc Stimulation ultrasonore de structures de tissu musculo-squelettique
EP3914347A4 (fr) * 2019-01-25 2023-03-01 Sonogen Medical, Inc. Stimulation ultrasonore de structures de tissu musculo-squelettique

Also Published As

Publication number Publication date
DE69532305T2 (de) 2004-10-21
AU3954695A (en) 1996-05-15
ATE255935T1 (de) 2003-12-15
DE69532305D1 (de) 2004-01-22
US5547459A (en) 1996-08-20
ES2210320T3 (es) 2004-07-01
EP0843573A1 (fr) 1998-05-27
WO1996012519A1 (fr) 1996-05-02
JPH10509605A (ja) 1998-09-22
US5752924A (en) 1998-05-19
EP0843573A4 (fr) 1999-07-21

Similar Documents

Publication Publication Date Title
EP0843573B1 (fr) Appareil de traitement de l'os par les ultrasons
US6652473B2 (en) Ultrasonic and growth factor bone-therapy: apparatus and method
Pilla Low-intensity electromagnetic and mechanical modulation of bone growth and repair: are they equivalent?
Kaufman et al. Ultrasound assessment of bone
US20090131838A1 (en) Method and system for the enhancement and monitoring of the healing process of bones
US6061597A (en) Method and device for healing bone fractures
EP2731675B1 (fr) Systèmes et procédés de couplage d'une source d'ultrasons à un tissu
US20020052634A1 (en) Method and system for modulation of oscillating signals to enhance biologic effects
Zhang et al. Coded excitation of ultrasonic guided waves in long bone fracture assessment
Baron et al. Interaction of ultrasound waves with bone remodelling: a multiscale computational study
KR101816090B1 (ko) 혈류 모니터링 기능을 갖는 초음파치료기
US20220184424A1 (en) Ultrasound stimulation of musculo-skeletal tissue structures
Saeki et al. FDTD simulation study of ultrasonic wave propagation in human radius model generated from 3D HR-pQCT images
Nyborg et al. Relevant field parameters with rationale
McLeod et al. Electromagnetic fields in bone repair and adaptation
Siddiqui et al. Acoustic sensing response in human tissues for theranostics and implants
JPS6247359A (ja) 骨用超音波刺激装置
JPS6247358A (ja) 超音波刺激装置
Eastwood et al. Sonoluminescence, in water and in human blood plasma, generated using ultrasonic therapy equipment
Clement Propagation of Focused Ultrasound in Tissue
RU2039579C1 (ru) Способ формирования сигнала физиотерапевтического воздействия и устройство для его осуществления
WO2000027335A1 (fr) Stimulateur et enregistreur par frequences de resonance
LT6759B (lt) Akustinių bangų poveikio žmogaus kūno organams įrenginys
Vigneshwari et al. Low-Frequency Ultrasound Therapeutic Device For Soft Tissue Healing
CN120393280A (zh) 超声驱动电刺激装置和效果评估的方法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19970523

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19990607

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 6A 61N 1/00 A, 6A 61N 7/00 B

17Q First examination report despatched

Effective date: 20011119

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

RTI1 Title (correction)

Free format text: ULTRASONIC BONE THERAPY APPARATUS

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20031210

Ref country code: LI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20031210

Ref country code: CH

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20031210

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20031210

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20031210

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 69532305

Country of ref document: DE

Date of ref document: 20040122

Kind code of ref document: P

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040310

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040310

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040310

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2210320

Country of ref document: ES

Kind code of ref document: T3

ET Fr: translation filed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20041004

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20041004

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20041004

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20041005

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20041031

26N No opposition filed

Effective date: 20040913

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050503

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20041004

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050630

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 20051004

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20041005

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040510